Metagenomi Therapeutics, Inc. (MGX) Quick Ratio
- Quick ratio · latest quarter: Value 4.37×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 4.37× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $120.66M ÷ $27.63M ≈ 4.37× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 120.66M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 27.63M USD | Liabilities, Current |
| Cash and equivalents | 39.03M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 81.64M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 0.00 USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $120.66M | $27.63M | $39.03M | $81.64M | $0.00 | (m) | 4.37× |
| 2026-03-31 | $140.16M | $22.50M | $25.31M | $114.86M | $0.00 | (m) | 6.23× |
| 2025-12-31 | (m) | $22.93M | $41.72M | $119.08M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $29.58M | $32.77M | $151.34M | (m) | (m) | (m) |
| 2025-06-30 | $205.89M | $33.27M | $26.85M | $178.14M | $900.00K | (m) | 6.19× |
| 2025-03-31 | $226.87M | $39.89M | $29.20M | $196.78M | $900.00K | (m) | 5.69× |
| 2024-12-31 | (m) | $37.31M | $27.39M | $220.92M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $45.69M | $25.12M | $249.47M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $52.81M | $61.18M | $238.74M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $70.70M | $102.56M | $224.85M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $68.86M | $140.60M | $130.58M | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | $101.90M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | $51.65M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $95.67M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |